Jasper Therapeutics, Inc. (JSPR) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 288K | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -288K | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | 100% | - | - | - | - | - | - | - |
| Operating Expenses | 10.93M | 15.84M | 19.17M | 27.08M | 21.8M | 25.29M | 19.89M | 15.99M | 14.78M | 17.73M | 19.36M | 17.83M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 5.12M | 4.48M | 4.78M | 5.88M | 5.64M | 5.51M | 5.43M | 4.7M | 4.49M | 3.89M | 4.51M | 4.53M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 5.81M | 11.36M | 14.39M | 21.2M | 16.16M | 19.77M | 14.46M | 11.3M | 10.3M | 13.84M | 14.85M | 13.3M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -10.95M | -15.84M | -19.17M | -27.08M | -21.8M | -25.29M | -19.89M | -15.99M | -15.07M | -17.73M | -19.36M | -17.83M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 49.77% | 37.36% | 3.64% | -69.3% | -44.65% | -42.65% | -2.72% | 10.29% | -8.07% | -28.94% | -52.36% | -49.02% |
| EBITDA | -10.93M | -15.55M | -18.94M | -26.82M | -21.52M | -25.04M | -19.35M | -15.69M | -14.78M | -17.44M | -19.09M | -17.55M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 49.21% | 37.9% | 2.12% | -70.88% | -45.58% | -43.56% | -1.37% | 10.59% | -8.13% | -29.45% | -53.42% | -49.44% |
| D&A (Non-Cash Add-back) | 21K | 290K | 229K | 258K | 279K | 245K | 541K | 299K | 288K | 283K | 276K | 275K |
| EBIT | -10.95M | -15.84M | -18.74M | -27.08M | -21.8M | -25.29M | -19.89M | -15.99M | -15.07M | -17.73M | -19.36M | -17.83M |
| Net Interest Income | 164K | 338K | 342K | 437K | 624K | 938K | 1.28M | 1.45M | 1.39M | 1.23M | 1.43M | 1.44M |
| Interest Income | 164K | 338K | 342K | 437K | 624K | 938K | 1.28M | 1.45M | 1.39M | 1.23M | 1.43M | 1.44M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 9.78M | 6.74M | 430K | 353K | 561K | 964K | 1.25M | 1.41M | 1.34M | 1.14M | 1.82M | 1.75M |
| Pretax Income | -1.17M | -9.1M | -18.74M | -26.72M | -21.24M | -24.32M | -18.64M | -14.58M | -13.73M | -16.58M | -17.54M | -16.08M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.17M | -9.1M | -18.74M | -26.72M | -21.24M | -24.32M | -18.64M | -14.58M | -13.73M | -16.58M | -17.54M | -16.08M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 94.47% | 62.58% | -0.53% | -83.25% | -54.73% | -46.68% | -6.23% | 9.31% | 3.73% | -25.51% | -47.89% | -54.56% |
| Net Income (Continuing) | -1.17M | -9.1M | -18.74M | -26.72M | -21.24M | -24.32M | -18.64M | -14.58M | -13.73M | -16.58M | -17.54M | -16.08M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.08 | -0.59 | -1.13 | -1.74 | -1.41 | -1.62 | -1.24 | -0.97 | -1.03 | -1.50 | -1.60 | -1.47 |
| EPS Growth % | 94.57% | 63.58% | 8.87% | -79.38% | -36.89% | -8% | 22.5% | 34.01% | 36.42% | 58.33% | 50.62% | 48.6% |
| EPS (Basic) | -0.06 | -0.47 | -1.13 | -1.74 | -1.41 | -1.62 | -1.24 | -0.97 | -1.03 | -1.50 | -1.60 | -1.47 |
| Diluted Shares Outstanding | 15.33M | 15.33M | 16.64M | 15.33M | 15.02M | 15.01M | 15M | 14.99M | 13.33M | 11.04M | 10.97M | 10.92M |
| Basic Shares Outstanding | 19.17M | 19.17M | 16.58M | 15.33M | 15.02M | 15.01M | 15M | 14.99M | 13.33M | 11.04M | 10.97M | 10.92M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |